By ZeiniX Life Sciences | In association with the Neuroimmunology Lab, Amrita Institute of Medical Sciences, Cochin
A Quiet Revolution in Neurology
Imagine a patient – a 45-year-old teacher – who begins forgetting words mid-sentence. Within weeks, she develops seizures. Psychiatrists call it a breakdown. MRI findings are equivocal. Months pass. The real culprit? An errant antibody, produced by her own immune system, attacking her brain.
This is not a rare story. It is, increasingly, a common one – and one that goes unrecognised far too often.
Autoimmune neurology is one of medicine’s most rapidly evolving frontiers. The central insight driving this revolution is both simple and profound: the immune system can target virtually any structure within the nervous system – the brain, spinal cord, peripheral nerves, or the junctions between nerve and muscle – producing a wide and often bewildering spectrum of neurological syndromes. Many of these conditions were, until recently, misattributed to psychiatric illness, degenerative disease, or idiopathic causes for which patients were told there was no answer.
There is now an answer. And it begins with the right test.
The Scale of What We Have Been Missing
For decades, autoimmune causes of neurological disease were considered curiosities – rare paraneoplastic phenomena occurring in cancer patients, identifiable by a handful of well-known antibodies. That picture has changed dramatically.
Research now shows that autoimmune encephalitis – to take just one condition – occurs at rates comparable to infectious encephalitis, yet is far less frequently diagnosed. Globally, landmark epidemiological work has confirmed that the prevalence and incidence of autoimmune encephalitis are on par with its infectious counterpart, and that detection rates are rising as awareness and testing improve. This is not because the disease is becoming more common; it is because we are finally looking for it with the right tools.
The breadth of autoimmune neurological disease is equally striking. Today, over 200 distinct neural autoantibodies have been characterised. Each points to a specific syndrome – a specific target within the nervous system, a specific clinical phenotype, and critically, a specific treatment pathway. These are not academic distinctions. They are the difference between a patient recovering and a patient deteriorating for years without a correct diagnosis.
In India, where the diagnostic infrastructure for this subspecialty has lagged significantly behind clinical need, the burden of missed or delayed diagnosis is particularly acute.
The Many Faces of Autoimmune Neurological Disease
Autoimmune neurology is not a single condition. It is a family of conditions, each with its own signature – and each requiring its own targeted investigation. At ZeiniX, we test across the full clinical spectrum:
Autoimmune Dementia – Cognitive decline caused not by neurodegeneration, but by antibody-mediated inflammation. A potentially reversible condition if identified early. Without autoimmune testing, these patients frequently receive an incorrect diagnosis of Alzheimer’s or another progressive dementia.
Autoimmune Epilepsy – New-onset seizures resistant to conventional anti-epileptic medications may have an immune-mediated cause. More than a dozen antibody biomarkers are now recognised as drivers of autoimmune epilepsy, each requiring a different management approach.
Autoimmune Encephalitis – Perhaps the most dramatic presentation in this field: rapid-onset psychiatric symptoms, memory disturbance, seizures, and movement abnormalities in a patient who was previously well. The NMDA-receptor antibody, the most commonly identified antibody in this condition, has transformed what was once a mysterious and frequently fatal encephalopathy into a treatable disease.
Autoimmune Neuropathy – Peripheral nerve damage driven by immune mechanisms, distinct from diabetic or toxic neuropathy in its cause and treatment. Accurate antibody identification guides whether a patient needs immunotherapy rather than symptomatic management alone.
CIDP, Nodopathy & Paranodopathy – Chronic inflammatory demyelinating polyneuropathy (CIDP) is now understood to be a heterogeneous group of conditions. A subset of patients – particularly those with antibodies targeting the node of Ranvier (such as anti-NF155, anti-CASPR1, and others) – have nodopathy or paranodopathy. These patients respond poorly to conventional CIDP therapies like IVIg, but may respond to different immune-targeted treatments. Misclassification means ineffective and expensive treatment for years.
Autoimmune Ataxia – Progressive unsteadiness and coordination loss caused by immune attack on the cerebellum. Early identification of specific antibodies (such as anti-GAD65, anti-CASPR2, and paraneoplastic antibodies) can halt progression.
Autoimmune Myelopathy – Spinal cord dysfunction driven by autoimmune inflammation. This includes conditions such as neuromyelitis optica spectrum disorder (NMOSD), with its distinctive AQP4-IgG antibody, and the more recently recognised GFAP astrocytopathy.
Atypical Parkinsonism – Not all movement disorders that resemble Parkinson’s disease are Parkinson’s disease. A subset are immune-mediated, identifiable by specific antibodies, and treatable with immunotherapy rather than dopaminergic drugs.
Stiff Person Spectrum Disorder (SPSD) – A comprehensive auto-antibody panel is essential in SPSD to capture the full spectrum of pathogenic antibodies, as relying on a single marker risks missed or delayed diagnosis. Broader testing improves diagnostic accuracy, enables earlier targeted therapy, and helps distinguish subtypes with differing prognostic and treatment implications.
The common thread across all these conditions: they are treatable – if caught in time, with the right diagnostic approach.
Why Early Testing Changes Everything
In autoimmune neurology, time is neural tissue.
Every day of unrecognised immune-mediated inflammation is a day of ongoing neuronal injury. Unlike degenerative diseases, many autoimmune neurological conditions can be arrested or even reversed – but the window for meaningful recovery narrows with each passing week. Patients with autoimmune encephalitis who receive immunotherapy promptly have substantially better functional outcomes than those in whom treatment is delayed.
Early testing also protects against the significant harm caused by misdiagnosis. A patient incorrectly diagnosed with a primary psychiatric disorder may receive antipsychotics and sedation, masking autoimmune symptoms and delaying recognition. A patient labelled with treatment-resistant epilepsy may undergo multiple medication trials when what they actually need is immunotherapy. These are not merely diagnostic inconveniences – they represent real deterioration in patient health, quality of life, and prognosis.
The economic case is equally compelling. Each inconclusive test, each failed medication trial, each unnecessary admission adds cost and patient distress. A focused autoimmune investigation ordered early – guided by the clinical syndrome – can terminate a diagnostic odyssey that might otherwise span years.
Why Syndrome-Specific Testing Is the Gold Standard
Here lies a critical point that separates modern autoimmune neurology practice from older diagnostic paradigms: not all autoimmune neurology panels are equal.
Traditional paraneoplastic evaluations – a legacy approach still widely used in India – test for a limited, fixed set of antibodies regardless of the patient’s clinical presentation. This approach carries two fundamental flaws.
First, it misses diagnoses. The antibodies most commonly responsible for autoimmune neurological disease – including NMDA-R IgG and GAD65, which together account for nearly half of all positive cases in autoimmune and paraneoplastic encephalitis – are often absent from these limited traditional panels. The result is a negative report, a falsely reassured clinician, and a patient who continues to deteriorate.
Second, it generates false positives. Some antibodies included in older panels – such as VGKC complex antibodies – have since been shown to lack clinical specificity and can lead to unnecessary immunotherapy, with all its attendant risks including severe infection and immune suppression.
The modern approach, validated by leading neuroimmunology centres globally, is phenotype-specific testing: matching the antibody panel to the patient’s clinical syndrome. A patient presenting with rapidly progressive dementia requires a different set of antibodies than a patient with new-onset epilepsy, or one with suspected spinal cord disease, or one with a peripheral neuropathy and paraprotein. Each phenotype carries its own antibody landscape, and testing must reflect that precision.
This is precisely the approach that underpins ZeiniX’s testing philosophy.
ZeiniX Life Sciences: India's Centre for Autoimmune Neurology Diagnostics
ZeiniX Life Sciences was established with a single purpose: to bring the global standard of autoimmune neurology diagnostics to India, making it accessible to neurologists and their patients across the country.
We are the official and exclusive industry partner of Amrita Institute of Medical Sciences, Cochin – one of India’s foremost academic medical institutions. All ZeiniX testing is conducted at the Neuroimmunology Laboratory at Amrita, which holds the distinction of being India’s first and only dedicated Centre of Excellence in Autoimmune Neurology. This is not merely a laboratory; it is a clinical-scientific ecosystem of neurologists, immunologists, and laboratory scientists working at the intersection of patient care and discovery.
Our testing menu spans the full spectrum of autoimmune neurological disease. We are continuously evolving and bringing in solutions tailor-made for Indian patients.
Every panel of ours is designed to match the clinical phenotype – because the right answer begins with the right question.
For the Neurologist: A New Standard of Practice
Autoimmune neurology demands specialist thinking. The complexity of clinical presentations, the nuance of antibody interpretation, and the implications of both false positives and false negatives require a diagnostic partner who understands this space deeply – not just as a testing service, but as a clinical science
At ZeiniX, our reports are not just numbers. They are interpreted within clinical context, with guidance designed to support the treating neurologist in reaching actionable conclusions. We combine the rigour of India’s only dedicated neuroimmunology centre with the accessibility that clinicians across India need.
We believe every neurologist in India should be able to ask the right question – and get a meaningful answer.
Conclusion: The Right Test, at the Right Time
The story of autoimmune neurology is ultimately a story of recognition – of conditions that were always there, affecting patients across every age group, every socioeconomic background, every part of the country, but going unrecognised because the tools to find them were unavailable or unused.
That story is changing. For patients whose immune systems have declared war on their own nervous systems, an accurate diagnosis is the beginning of recovery. Early testing – targeted, syndrome-specific, and grounded in clinical expertise – is how we get them there.
This is the mission of ZeiniX. This is what the Neuroimmunology Lab at Amrita makes possible.
References
- ZeiniX Life Sciences is the official and exclusive industry partner of Amrita Institute of Medical Sciences, Cochin.
- All autoimmune neurology testing is performed at the Neuroimmunology Laboratory at Amrita – India’s first and only dedicated Centre of Excellence in Autoimmune Neurology.
- For test ordering, clinical queries, or to learn more about our diagnostic menu, contact us at
